To prevent the spread of tuberculosis (TB) and limit the development of drug-resistant strains, the World Health Organization and the Canadian TB Standards recommend Directly Observed Therapy (DOT) for TB patients. 1, 2 In Toronto, DOT is conducted by Toronto Public Health (TPH) staff who visit patients with active TB 3 to 7 days/week over the course of their treatment (i.e., 6 to 24 months) to monitor their adherence and response to medications and to support the patient to complete treatment successfully. For medically stable and compliant patients with active TB, TPH has initiated the use of Videophone DOT (VDOT) as a supplement to Community DOT (CDOT). In VDOT, DOT visits are conducted using videophones, which are telephones with a small video screen streaming real-time video and audio. A secure virtual link is established over the internet with videophones located in both the patient's home and the public health office. To be eligible for VDOT, patients must meet stringent criteria, including medical stability, adherence to treatment, access to high-speed internet, and completion of at least four weeks of CDOT treatment. The VDOT program was developed to increase our capacity, flexibility, and efficiency of providing DOT.
The time required to conduct a VDOT visit (including visit time, travel, and documentation) is 10 minutes, on average, which is significantly less than the 36 minutes for a CDOT visit (ratio = 3.60 VDOT visits: 1 CDOT visit). Both patients and health unit staff report high satisfaction with VDOT, in particular flexibility, privacy, and more efficient visits.
A drawback of VDOT, reported by both patients and staff, was diminished interpersonal interaction. In addition, conducting a physical assessment over a videophone can be difficult, particularly if picture quality is poor. Most technical issues were concentrated among a few patients, indicating that the quality of an individual patient's internet connection plays a significant role in the quality of transmission.
Based on these overall positive results, TPH has made technical improvements and expanded VDOT to approximately 35 patients (25% of total cases). In conclusion, for stable, adherent patients, we believe that VDOT is a very useful mode of service delivery that facilitates patient support throughout treatment while enhancing privacy and flexibility. In the upcoming year, we plan to investigate other possible solutions to keep pace with changing technology and facilitate increased access to VDOT for eligible patients. 
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